Page 2 - Biosimilar Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biosimilarity

Enhancing access to biosimilars in the US involves multiple key factors, including active participation from payers, providers, and the healthcare community to incentivize the utilization of biosimilars.

The global clinical trials market was estimated to be worth $38.7 billion in 2021 and is expected to reach £52 billion by 2026. In this article, we look at the top 12 CROs in the world, highlighting the companies driving this considerable growth and accelerating research and development across the globe ...

Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1987 at Raichur, Karnataka. The commercial production in the SML was started in November 1989. Today SML, with a consolidated revenue of R 1,159.76 crore for the year 2021-22 against the previous years’ revenue of Rs 931.27 crore, has emerged as a global brand within manufacturing and supplying of affordable API and Formulation globally in different regulated markets. The Group with over 20 subsidiaries is now setting up a greenfield project located in Karnataka. BioSpectrum India spoke to Vishnukant Bhutada...

This Week in Washington: The Senate waits to see if budget reconciliation agreement has enough votes to pass.